+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetic Nephropathy - Pipeline Review, H2 2019

  • ID: 4866577
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 250 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aibios Co Ltd
  • Bayer AG
  • CSL Ltd
  • GNI Group Ltd
  • Mesoblast Ltd
  • ProKidney LLC
  • MORE
Diabetic Nephropathy - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2019, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 18, 16, 25, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aibios Co Ltd
  • Bayer AG
  • CSL Ltd
  • GNI Group Ltd
  • Mesoblast Ltd
  • ProKidney LLC
  • MORE
Introduction
Diabetic Nephropathy - Overview
Diabetic Nephropathy - Therapeutics Development
Diabetic Nephropathy - Therapeutics Assessment
Diabetic Nephropathy - Companies Involved in Therapeutics Development
Diabetic Nephropathy - Drug Profiles
Diabetic Nephropathy - Dormant Projects
Diabetic Nephropathy - Discontinued Products
Diabetic Nephropathy - Product Development Milestones
Appendix

List of Tables
Table 1: Number of Products under Development for Diabetic Nephropathy, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Universities/Institutes, H2 2019
Table 6: Products under Development by Companies, H2 2019
Table 7: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 8: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 9: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 10: Products under Development by Universities/Institutes, H2 2019
Table 11: Number of Products by Stage and Target, H2 2019
Table 12: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 13: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Table 14: Number of Products by Stage and Mechanism of Action, H2 2019
Table 15: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 16: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Table 17: Number of Products by Stage and Route of Administration, H2 2019
Table 18: Number of Products by Stage and Molecule Type, H2 2019
Table 19: Diabetic Nephropathy - Pipeline by Aibios Co Ltd, H2 2019
Table 20: Diabetic Nephropathy - Pipeline by Algomedix Inc, H2 2019
Table 21: Diabetic Nephropathy - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2019
Table 22: Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H2 2019
Table 23: Diabetic Nephropathy - Pipeline by APT Therapeutics Inc, H2 2019
Table 24: Diabetic Nephropathy - Pipeline by AptaBio Therapeutics Inc, H2 2019
Table 25: Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals Inc, H2 2019
Table 26: Diabetic Nephropathy - Pipeline by Astellas Pharma Inc, H2 2019
Table 27: Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H2 2019
Table 28: Diabetic Nephropathy - Pipeline by Bayer AG, H2 2019
Table 29: Diabetic Nephropathy - Pipeline by Betagenon AB, H2 2019
Table 30: Diabetic Nephropathy - Pipeline by Bird Rock Bio Inc, H2 2019
Table 31: Diabetic Nephropathy - Pipeline by BLR Bio LLC, H2 2019
Table 32: Diabetic Nephropathy - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Table 33: Diabetic Nephropathy - Pipeline by CCRP Therapeutics GmbH, H2 2019
Table 34: Diabetic Nephropathy - Pipeline by Cellmid Ltd, H2 2019
Table 35: Diabetic Nephropathy - Pipeline by Certa Therapeutics Pty Ltd, H2 2019
Table 36: Diabetic Nephropathy - Pipeline by ChemoCentryx Inc, H2 2019
Table 37: Diabetic Nephropathy - Pipeline by Corbus Pharmaceuticals Inc, H2 2019
Table 38: Diabetic Nephropathy - Pipeline by CSL Ltd, H2 2019
Table 39: Diabetic Nephropathy - Pipeline by cStem Regeneration Pharmaceutical Co Ltd, H2 2019
Table 40: Diabetic Nephropathy - Pipeline by Curacle Co Ltd, H2 2019
Table 41: Diabetic Nephropathy - Pipeline by Cyclerion Therapeutics Inc, H2 2019
Table 42: Diabetic Nephropathy - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Table 43: Diabetic Nephropathy - Pipeline by Dimerix Bioscience Pty Ltd, H2 2019
Table 44: Diabetic Nephropathy - Pipeline by Future Medicine Co Ltd, H2 2019
Table 45: Diabetic Nephropathy - Pipeline by GenKyoTex SA, H2 2019
Table 46: Diabetic Nephropathy - Pipeline by Gilead Sciences Inc, H2 2019
Table 47: Diabetic Nephropathy - Pipeline by Glycadia Inc, H2 2019
Table 48: Diabetic Nephropathy - Pipeline by GNI Group Ltd, H2 2019
Table 49: Diabetic Nephropathy - Pipeline by Goldfinch Biopharma Inc, H2 2019
Table 50: Diabetic Nephropathy - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, H2 2019
Table 51: Diabetic Nephropathy - Pipeline by Inspyr Therapeutics Inc, H2 2019
Table 52: Diabetic Nephropathy - Pipeline by Johnson & Johnson, H2 2019
Table 53: Diabetic Nephropathy - Pipeline by Liminal BioSciences Inc, H2 2019
Table 54: Diabetic Nephropathy - Pipeline by MediPost Co Ltd, H2 2019
Table 55: Diabetic Nephropathy - Pipeline by Merck & Co Inc, H2 2019
Table 56: Diabetic Nephropathy - Pipeline by Mesoblast Ltd, H2 2019
Table 57: Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019
Table 58: Diabetic Nephropathy - Pipeline by Novartis AG, H2 2019
Table 59: Diabetic Nephropathy - Pipeline by Novo Nordisk AS, H2 2019
Table 60: Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H2 2019

List of Figures
Figure 1: Number of Products under Development for Diabetic Nephropathy, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aibios Co Ltd
  • Algomedix Inc
  • Allist Shanghai Pharmaceutical Technology Co Ltd
  • Antisense Therapeutics Ltd
  • APT Therapeutics Inc
  • AptaBio Therapeutics Inc
  • Araim Pharmaceuticals Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • Betagenon AB
  • Bird Rock Bio Inc
  • BLR Bio LLC
  • Boehringer Ingelheim International GmbH
  • CCRP Therapeutics GmbH
  • Cellmid Ltd
  • Certa Therapeutics Pty Ltd
  • ChemoCentryx Inc
  • Corbus Pharmaceuticals Inc
  • CSL Ltd
  • cStem Regeneration Pharmaceutical Co Ltd
  • Curacle Co Ltd
  • Cyclerion Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Dimerix Bioscience Pty Ltd
  • Future Medicine Co Ltd
  • GenKyoTex SA
  • Gilead Sciences Inc
  • Glycadia Inc
  • GNI Group Ltd
  • Goldfinch Biopharma Inc
  • Guangzhou Magpie Pharmaceutical Co Ltd
  • Inspyr Therapeutics Inc
  • Johnson & Johnson
  • Liminal BioSciences Inc
  • MediPost Co Ltd
  • Merck & Co Inc
  • Mesoblast Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Novartis AG
  • Novo Nordisk AS
  • Noxxon Pharma AG
  • Orbsen Therapeutics Ltd
  • Paranta Biosciences Ltd
  • PhytoHealth Corp
  • ProKidney LLC
  • Reata Pharmaceuticals Inc
  • Redx Pharma Plc
  • Sarfez Pharmaceuticals Inc
  • Scohia Pharma Inc
  • Serodus ASA
  • Sulfateq BV
  • Teijin Pharma Ltd
  • Theravance Biopharma Inc
  • Twoxar Inc
  • Vidasym Inc
  • ZyVersa Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll